Bio News
Inventera has received the final clinical study report for the domestic phase 3 trial of INV-002, a contrast agent specifically developed for magnetic resonance arthrography (MRA).
Compared with noncontrast MRI, INV-002 demonstrated statistically significant improvements in joint distension, contrast, and clarity.
Based on these results, Inventera plans to submit a marketing authorization application to the Ministry of Food and Drug Safety.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
